A critical appraisal of platelet glycoprotein IIb/IIIa inhibition

Journal of the American College of Cardiology

Volumn 36, Issue 7, 2000, Pages 2028-2035

  Chew, Derek P ^a   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR;

APOPTOSIS; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INDIVIDUALIZATION; ISCHEMIC HEART DISEASE; MORTALITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR DENSITY; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SUDDEN DEATH; THROMBOCYTE;

EID: 0033673103     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00979-7     Document Type: Article

References (63)

1. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: The EPIC Investigation
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: The EPILOG Investigators
4. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators
5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
8. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
9. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
10. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
11. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A pooled analysis of the large scale oral glycoprotein IIb/IIIa trials
12. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
13. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses
14. Integrin signaling in vascular biology
15. Ligand inhibition of the platelet glycoprotein IIb-IIIa complex function as a calcium channel in liposomes
16. Ligands 'activate' integrin alpha IIb beta 3 (platelet GPIIb-IIIa)
17. How important is unfractionated heparin as adjunctive pharmacotherapy with GP IIb/IIIa antagonists in acute coronary syndromes
18. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
19. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin
20. Potential nonglycoprotein IIb/IIIa effects of abciximab
21. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
22. High-dose abciximab during coronary angioplasty in a patient with essential thrombocytosis
23. Altered platelet function detected by flow cytometry: Effects of coronary artery disease and age
24. Gender differences in platelet GPIIb-IIIa activation
25. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus
26. Platelet GPIIIa P1(A) polymorphisms display different sensitivities to agonists
27. The P1(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions
28. Expression of markers of platelet activation and the interpatient variation in response to abciximab
29. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
30. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
31. Marked variability in inhibition of fibrinogen binding to platelets by tirofiban and abciximab in acute coronary syndromes
32. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade
33. Time course, magnitude and consistency of platelet inhibition by abciximab, tirofiban or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
34. Bleeding complications with the chimeric antibody to platelet glycoprotein IIB/IIIa integrin in patients undergoing percutaneous coronary intervention
35. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction
36. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the Thrombolysis in Myocardial Infarction (TIMI) 12 trial
37. Orbofiban in patients with unstable coronary syndromes thrombolysis in myocardial infarction 16
38. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial
39. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors
40. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy
41. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience
42. Thrombocytopenia, bleeding and thrombotic events with oral glycoprotein IIb/IIIa inhibition. Results from OPUS TIMI 16
43. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement
44. Tirofiban, eptifibatide, but not abciximab, leukocyte-platelet aggregation
45. RGD peptides induce apoptosis by direct caspase-3 activation
46. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
47. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
48. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II
49. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
50. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
51. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC). Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade (EPILOG)
52. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
53. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
54. Clinical pharmacology of eptifibatide
55. Early percutaneous coronary intervention, platelet inhibition with eptifibatide and clinical outcomes in patients with acute coronary syndromes
56. A prospective multicenter study to determine the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention - The GOLD study
57. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
58. Heparin use is required for clinical benefit of GIIb/IIIa inhibitor eptifibatide in acute coronary syndromes: Insights from the PURSUIT trial
59. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. Evaluation of oral xemilofiban in controlling thrombotic events
60. A randomized comparison of sibrafiban, an oral glycoprotein (GP) IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes (ACS): Results of the second SYMPHONY trial
61. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention
62. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment
63. Pharmacodynamic efficacy, clinical safety and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial